Langerhans-type dendritic cells electroporated with TRP-2 mRNA stimulate cellular immunity against melanoma: Results of a phase I vaccine trial

Langerhans-type dendritic cells electroporated with TRP-2 mRNA stimulate cellular immunity against melanoma: Results of a phase I vaccine trial

Purpose: We conducted a phase I vaccine trial to determine safety, toxicity, and immunogenicity of autologous Langerhans-type dendritic cells (LCs), electroporated with murine tyrosinase-related peptide-2 (mTRP2) mRNA in patients with resected AJCC stage IIB, IIC, III, or IV (MIa) melanoma. Experime...

Full description

Bibliographic Details
Main Authors: David J. Chung, Richard D. Carvajal, Michael A. Postow, Sneh Sharma, Katherine B. Pronschinske, Justin A. Shyer, Shahnaz Singh-Kandah, Mark A. Dickson, Sandra P. D'Angelo, Jedd D. Wolchok, James W. Young
Format: Article
Language:English
Published: Taylor & Francis Group 2018-01-01
Series:OncoImmunology
Subjects:
langerhans-type dendritic cell
clinical immunology
cancer vaccines
phase i trial
melanoma
Online Access:http://dx.doi.org/10.1080/2162402X.2017.1372081

Internet

http://dx.doi.org/10.1080/2162402X.2017.1372081

Similar Items